参芪补肺汤加减联合孟鲁司特钠治疗非小细胞 肺癌术后慢性咳嗽的临床研究.

OBJECTIVE: To probe into the clinical efficacy of modified Shenqi Bufei decoction combined with montelukast sodium in the treatment of chronic cough after non-small cell lung cancer surgery. METHODS: Totally 104 patients with chronic cough after non-small cell lung cancer suegery admitted into the hospital from Jun. 2020 to Jun. 2022 were extracted to be divided into the control group and the observation group via the random number table method, with 52 cases in each group. The control group was treated with Montelukaster sodium tablets, while the observation group received Shenqi Bufei decoction based on the control group. The cough symptom score, Lessister cough quality of life score, serum humoral immune indicators [immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin G (IgG)], serum inflammatory cytokines [C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)] before and after treatment and safety were observed in two groups. RESULTS: After treatment, daytime cough symptom score, nighttime cough symptom score, CRP, IL-6 and TNF-α levels in both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0. 05). After treatment, Lycester cough life quality score, IgA, IgM and IgG levels in both groups were higher than those before treatment, and the observe group was higher than the control group, with statistically significant difference (P < 0. 05). CONCLUSIONS: Shenqi Bufei decoction combined with montelukast sodium can reduce the occurrence of chronic cough after non-small cell lung cancer surgery, reduce cough symptom score and serum inflammatory factor expression, and improve the immune function and quality of life of patients. [ABSTRACT FROM AUTHOR]